ClinicalTrials.Veeva

Menu

Enhancing Heart Allograft Function With the OCS Heart System Trial (ENHANCE)

TransMedics logo

TransMedics

Status

Enrolling

Conditions

Heart Transplant

Treatments

Device: OCS Heart
Other: Static Cold Storage (SCS)

Study type

Interventional

Funder types

Industry

Identifiers

NCT07145515
OCS-HEART-031725

Details and patient eligibility

About

This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.

Enrollment

655 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Part A - DCD Donor Hearts & DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications):

Donor Inclusion Criteria

  • Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.

  • All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is <50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor.

  • DBD donor hearts with an expected cross clamp of ≥ 4 hours

  • DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time:

    • Donor age ≥ 40 years old
    • Unknown downtime
    • Insignificant CAD
    • LVEF ≤ 50%

Donor Exclusion • Moderate to severe aortic incompetence

Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication):

Donor Inclusion Criteria

  • Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
  • Eligible for randomization to OCS or SCS treatment arms.
  • DBD donor hearts with an expected cross clamp time of < 4 hours.

Donor Exclusion

  • Moderate to severe aortic incompetence

  • DBD donor with any of the following organ quality concerns:

    • Donor age ≥ 40 years old
    • Unknown downtime
    • Insignificant CAD
    • LVEF ≤ 50%

Recipient Eligibility Criteria (for Part A and B Cohorts)

Inclusion

  • Signed informed consent document and authorization to use and disclose protected health information
  • Heart transplant candidate
  • Age ≥ 18 years old

Exclusion

• Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

655 participants in 3 patient groups

Part A (OCS Heart)
Experimental group
Description:
DCD Donor Hearts \& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications)
Treatment:
Device: OCS Heart
Part B (OCS Heart)
Experimental group
Description:
DBD Donor Hearts Currently Used with Cold Storage
Treatment:
Device: OCS Heart
Part B (SCS)
Active Comparator group
Description:
DBD Donor Hearts Currently Used with Cold Storage
Treatment:
Other: Static Cold Storage (SCS)

Trial contacts and locations

8

Loading...

Central trial contact

Kausar Qidwai; Raicca Haqqi

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems